3.24
溶解に影響する要因: 多形性、非晶性、擬似多形性
多形性とは、薬物物質が複数の結晶形態（多形体）で存在することを意味します。最近、この用語は、溶媒和物（溶媒を含む形態）、非晶質形態（非結晶形態）、および脱溶媒和された溶媒和物（溶媒が除去された形態）を含むように拡張されました。
一部の多形結晶は非晶質結晶よりも水溶性が低く、吸収が不完全になります。た…
薬物溶解は、多形、溶媒和物、非晶質形態などの複数の結晶形態の原薬の存在を指す多形の影響を受けます。
薬物の多形は、同じ化学式を共有していますが、化学構造が異なるため、異なる物理的特性を示します。
例えば、クロラムフェニコール懸濁液は複数の結晶形態を有する。しかし、溶解性の高いβ-多形の割合が高いほど、薬物の吸収が促進されます。
準安定多形は、製造中により安定した形状に変換され、錠剤の亀裂や造粒圧縮の防止などの問題を引き起こす可能性があります。
製造過程で、一部の薬物は溶媒と相互作用して溶媒和物を形成します。これらの溶媒和物のさまざまな結晶形態は、擬似多形と呼ばれます。
溶媒が水の場合、水和物が形成されます。エリスロマイシン水和物の場合、溶解率と時間のプロットは、二水和物、一水和物、および無水物の形態について異なる溶解度パターンを示しています。
最後に、アモルファス形態は結晶構造を欠いており、結晶よりも水溶液に急速に溶解します。
View the full transcript and gain access to JoVE Core videos
Q1: What is polymorphism and how does it affect drug dissolution?
Polymorphism refers to a drug substance existing in multiple crystalline forms with the same chemical formula but different structures and physical properties. Different polymorphs exhibit varying solubility rates; for example, chloramphenicol's highly soluble β-polymorph enhances drug absorption compared to less soluble forms. This variation directly impacts dissolution rates and bioavailability.
Q2: Why do metastable polymorphs cause problems during drug manufacturing?
Metastable polymorphs can convert to more stable forms during manufacturing, causing tablet cracking or preventing granulation compression. These transitions occur because metastable forms possess higher free energy than stable polymorphs. Such changes may require product reformulation to maintain pharmaceutical quality and efficacy.
Q3: What are solvates and pseudopolymorphs in pharmaceutical formulations?
Solvates form when drugs interact with solvents during manufacturing. When water is the solvent, specific crystalline forms called hydrates are produced. These pseudopolymorphs possess different solubility characteristics than their anhydrous counterparts; for instance, erythromycin hydrates show distinct dissolution patterns compared to the anhydrate form.
Q4: How do amorphous drug forms compare to crystalline forms in dissolution?
Amorphous forms lack crystalline structures and dissolve more rapidly in aqueous solutions than crystalline forms. Being less structurally rigid, amorphous drugs often exhibit faster dissolution rates. However, some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, potentially leading to incomplete absorption.
Q5: Why does anhydrous ampicillin absorb faster than ampicillin trihydrate?
The anhydrous form of ampicillin dissolves more quickly than ampicillin trihydrate, resulting in faster absorption. This difference stems from the distinct solubility characteristics of hydrated versus anhydrous forms. Faster dissolution of the anhydrous form enables more rapid drug availability for mechanisms of drug absorption paracellular transcellular and vesicular transport.
Q6: What determines whether a polymorph is stable or metastable?
The most stable polymorph has the lowest free energy, making it thermodynamically favored. Metastable polymorphs possess higher free energy and may spontaneously transition to more stable forms over time. This energy difference explains why certain crystal forms persist during manufacturing while others convert, potentially causing formulation problems.
Q7: How do hydrate forms of erythromycin differ in their dissolution behavior?
Erythromycin exists in dihydrate, monohydrate, and anhydrate forms, each displaying different solubility patterns. When percent dissolved is plotted against time, these hydrate forms show distinct dissolution curves. The variation in water content directly influences the crystal structure and aqueous solubility of each form.